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Abstract
The excitatory amino acid transporters 1 and 2 (EAAT1 and EAAT2), mostly located on 
astrocytes, are the main mediators for glutamate clearance in humans. Malfunctions of these 
transporters may lead to excessive glutamate accumulation and subsequent excitotoxicity to 
neurons, which has been implicated in many kinds of neurodegenerative disorders including 
Alzheimer’s disease (AD). Yet, the specific mechanism of the glutamate system dysregulation 
remains vague. To explore whether the insulin/protein kinase B (Akt)/EAAT signaling in human 
astrocytes could be disturbed by beta-amyloid protein (Aβ) and be protected by insulin, we 
incubated HA-1800 cells with varying concentrations of Aβ1–42 oligomers and insulin. Then the 
alterations of several key substrates in this signal transduction pathway were determined. Our 
results showed that expressions of insulin receptor, phospho-insulin receptor, phospho-protein 
kinase B, phospho-mammalian target of rapamycin, and EAAT1 and EAAT2 were decreased by 
the Aβ1–42 oligomers in a dose-dependent manner (p < 0.05) and this trend could be recovered by 
insulin treatment (p < 0.05). However, the expressions of total Akt and mTOR were invariant (p > 
0.05), and the mRNA levels of EAAT1 and EAAT2 were also unchanged (p > 0.05). Taken 
together, this study indicates that Aβ1–42 oligomers could cause disturbances in insulin/Akt/EAAT 
signaling in astrocytes, which might be responsible for AD onset and progression. Additionally, 
insulin can exert protective functions to the brain by modulating protein modifications or 
expressions.
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Alzheimer’s disease (AD), which is an age-related neurodegenerative disorder, is the most 
common form of dementia among old people. It is a heterogeneous disease that affected 1.93 
million people in China in 1990 and 5.69 million in 2010 (Chan et al. 2013). Clinically, AD 
is characterized by the insidious onset and gradual progression of cognitive decline. The 
well-known histopathological changes namely extracellular senile plaques (SPs) depositing 
of beta-amyloid protein (Aβ), neurofibrillary tangles (NFTs) consisting of 
hyperphosphorylated tau protein, as well as damage to neurons represents the effects of 
brain insulin resistance and deficiency (de la Monte 2014). Although the pathogenesis of AD 
is still elusive, there is ample consensus that the abnormal Aβ deposition in the central 
nervous system (CNS) plays a crucial role, especially the Aβ1–42 in the form of soluble 
oligomers (Tam and Pasternak 2012). Additionally, disturbances in insulin signaling and 
abnormalities of the glutamate neurotransmitter system are also involved in AD (On 2013a; 
Kulijewicz-Nawrot et al. 2013).
Brain insulin signaling has been widely researched in the last decade. It is critical for 
memory processing, synaptic genesis and remodeling. Furthermore, insulin is a kind of 
neuroprotective hormone that contributes not only to metabolism but also to cognition (Chen 
et al. 2014). Several recent reports have indicated that both brain IR density and insulin level 
decrease with age (Cole and Frautschy 2007; Laron 2009) and many key substrates in the 
insulin signal transduction pathway are significantly reduced in AD (Liu et al. 2011; 
Pearson-Leary and McNay 2012). Furthermore, mammalian target of rapamycin (mTOR), 
one of the most important downstream targets of protein kinase B (Akt), can regulate 
glutamate transporter expression in astrocytes (Lopez-Colome et al. 2012). A number of 
studies have shown that direct exposure to Aβ could result in animal cognitive decline and 
downregulation of Akt and mTOR (Caccamo et al. 2010; Pearson-Leary and McNay 2012).
Astrocytes are the major glial cells in the CNS providing a nurturing environment for 
neurons. To be specific, they contribute to synaptic functions, transfer and storage 
information, participate in cognition, produce trophic factors, remove toxins and debris, 
maintain redox potential and regulate concentrations of neurotransmitters and ions (Sidoryk-
Wegrzynowicz et al. 2011). In addition, astrocytes express abundant insulin receptors (IRs) 
and can be influenced by insulin (Henneberger et al. 2010). Furthermore, it has been 
reported that astrocyte dysfunction is associated with AD (Birch 2014). Glutamate, the main 
excitatory neurotransmitter in the brain, plays a key role in learning and memory. It is 
released into the synaptic cleft during neuron activity and rapidly taken up by the excitatory 
amino acid transporters (EAATs), among which EAAT1 and EAAT2 (known in rodents as 
glutamate/aspartate transporter, GLAST, and glutamate transporter-1, GLT-1) preferentially 
located in astrocytes are responsible for clearance of the majority of glutamate (Danbolt 
2001). Consequently, malfunctions of EAAT1 and EAAT2 may lead to aberrant glutamate 
accumulation and neuron injury known as excitotoxicity.
Although a great deal of evidence has revealed that insulin signaling disturbances and 
glutamate neurotoxicity are implicated in AD pathophysiology, it remains to be determined 
how Aβ oligomers are related to glutamate excitotoxicity. The aim of this study was to 
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explore whether the insulin/Akt/EAAT signaling in human astrocytes could be disturbed by 
Aβ and if insulin has protective effects on the cells. Hence, we treated human astrocytes 
with Aβ1–42 oligomers and insulin, and then investigated the changes of downstream targets 
in this signaling pathway both in protein expressions and mRNA levels.
Materials and Methods
Preparation of Aβ1–42 Oligomers
The method employed to generate Aβ1–42 oligomers was described by Ryan et al. (Ryan et 
al. 2010). Briefly, 1 mg human synthetic Aβ1–42 lyophilized powder (American Peptide 
Sunnyvale, CA, USA) was suspended in 1,1,1,3,3,3-hexa-fluoro-2-propanol (HFIP, Sigma, 
Saint Louis, MO, USA) to 1 mM concentration, followed by vibration mixing to produce a 
homogenous suspension. Subsequently, the suspension was aliquoted into five microfuge 
tubes and the HFIP was removed in a ventilation cabinet overnight, leaving a hyaloid peptide 
film. The peptide film was resuspended in anhydrous dimethyl sulfoxide (DMSO, Sigma, 
Saint Louis, MO, USA) to 5 mM and sonicated for 10 min. Then the dimethyl sulfoxide-
Aβ1–42 solution was diluted with cold PBS containing 0.05 % SDS to 100 μM followed by a 
24-h incubation at 4 °C. For higher aggregation, the peptide solution was further diluted with 
PBS to 11.1 μM and incubated for another 2 weeks at 4 °C. For experiments, these Aβ1–42 
oligomer preparations were centrifuged at 13,000 rpm for 10 min to remove the insoluble 
aggregates and diluted to final concentrations with serum-free Dulbecco’s modified Eagle’s 
medium (DMEM, low-glucose, Carlsbad, CA, USA).
Identification of Aβ1–42 Oligomers
Aβ1–42 oligomeric preparations were identified by transmission electron microscopy 
(H-800, Japan’s Hitachi). Briefly, 20 μL Aβ1–42 oligomeric preparation was spotted onto a 
copper mesh and dried for 10 min followed by washing twice with distilled water. Then, it 
was stained with 2 % phosphotungstic acid (pH 6.8) for 2 min, washed once, dried, and 
examined. The acceleration voltage was 100 kV and the magnification was ×100,000.
Astrocyte Culture
Human astrocyte cell line (HA-1800) was obtained from ScienCell Research Laboratories 
(ScienCell, Carlsbad, CA, USA). Cells were grown in low-glucose DMEM containing 10 % 
fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) and maintained in a humidified 5 % 
CO2 atmosphere at 37°C.
Pharmacological Treatments
The astrocytes were plated in 25 cm2 culture flasks at 2.0 × 105 cells/mL for Western blot 
and real-time PCR analyses. Cells were plated onto poly-D-lysine-coated 24-well chamber 
slides at 1.0 × 105 cells/well for immunofluorescence staining analysis, and plated in 96-
well plates at 9.0 × 103 cells/well for MTT analysis. There were six groups in our 
experiments: control group and groups I to V. The control group, group I, and group II were 
successively treated with equivalent volumes of FBS-free DMEM, 100 nM Aβ1–42 
oligomers and 1 μM Aβ1–42 oligomers for 24 h (Ferreira et al. 2012; Ito et al. 2012; Zhou et 
al. 2012); groups III, IV, and V were treated with 100 nM human recombinant insulin (Novo 
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Nordisk, Bagsvard, Denmark) for 30 min after the treatments with DMEM vehicle, 100 nM 
Aβ1–42 oligomers and 1 μM Aβ1–42 oligomers, respectively (Bomfim et al. 2012; De Felice 
et al. 2009; Ji et al. 2011).
RNA Isolation and Real-Time RT-PCR Analysis
Total RNA was isolated from astrocytes according to the manufacturer’s protocol for 
RNAiso Plus (TakaRa, Dalian, China). RNA concentration was measured by 
spectrophotometric absorbance at 260 nm and 1 μg total RNA was reverse transcribed using 
a Prime Script RT reagent kit (TakaRa, Dalian, China). Quantitative real-time PCR analysis 
was performed by the LightCycler Carousel-Based System (Roche Applied Science, 
Mannheim, Germany) with a SYBR Premix Ex Taq (Tli RNaseH Plus) kit (TakaRa, Dalian, 
China). The shuttle PCR conditions were as follows: initial denaturation at 95 °C for 30 s 
followed by 40 cycles of denaturation at 95 °C for 5 s, annealing at 55 °C for 30 s, and 
extension at 72 °C for 30 s. After shuttle PCR, a melting curve was constructed by 
increasing the temperature to 95 °C. β-actin was used as an endogenous control for 
normalization of RNA quantity. Relative changes of gene expression were calculated using 
the comparative ΔΔCt method. This procedure was repeated three times for each gene. All 
primers purchased from Sangong Biotech (Shanghai, China) were as follows:
GFAP forward primer: 5′-CTGGAGGTTGAGAGGGA CAAT-3′; reverse primer: 5′-
GTGGCTTCATCTGCTTCC TGT-3′; IR forward primer: 5′-TTTCGTCCCCAGAAAA 
ACCTCT-3′; reverse primer: 5′-CCACCGTCATCCCAA C-3′; Akt forward primer: 5′-
GGTATTTTGATGAGGAG TTCACG-3′; reverse primer: 5′-GAGTAGGAGAACTGG 
GGGAAGT-3′; mTOR forward primer: 5′-CTTGTTTGTG GCTCTGAATGAC-3′; reverse 
primer: 5′-GGCACTCTG CTCTTTGATTCTT-3′; EAAT1 forward primer: 5′-GCTT 
ACTCATTCACGCAGTCAT-3′; reverse primer: 5′-AAC 
CCTCCAATAAAAACCCAAG-3′; EAAT2 forward primer: 5′-
GGTCATTCTGGTCTTGGCTATC-3′; reverse primer: 5′-
AGGCTGGACACTTCATCATTCT-3′; β-actin forward primer: 5′-
TGACGTGGACATCCGCAAAG-3′; reverse primer: 5′-
CTGGAAGGTGGACAGCGAGG-3′.
Western Blot Analysis
After the treatment, the cells were lysed for 30 min in ice-cold RIPA lysis buffer (Beyotime, 
Haimen, China) containing phenylmethanesulfonyl fluoride (PMSF, Beyotime, Haimen, 
China) and protein phosphatase inhibitor complex I (Aidlab Biotechnologies, Beijing, 
China) to extract total proteins. The protein content was measured using a BCA protein 
assay kit (Beyotime, Haimen, China), adjusted to 30 μg, and then subjected to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE with 10 % acrylamide gel). Subsequently, 
the separated proteins were electroblotted onto polyvinylidene difluoride (PVDF) 
membranes (Millipore, Bedford, MA, USA) and blocked with 5 % bovine serum albumin 
(BSA, Sigma, Saint Louis, MO, USA) in Tris-buffered saline Tween-20 (TBST, 50 mM 
Tris–HCl, 150 mM NaCl, pH 7.4, 0.1 % Tween-20) for 1 h at room temperature. Then the 
membranes were incubated with primary antibodies at 4 °C overnight as follows: mouse 
monoclonal anti-GFAP (1:200, Abcam, Cambridge, UK); rabbit polyclonal anti-insulin 
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receptor alpha (1:200, Abcam, Hong Kong, China); rabbit polyclonal anti-insulin receptor 
beta (1:500, ImmunoWay, Newark, DE, USA); rabbit polyclonal anti-phospho-insulin 
receptor (Y1361, 1:500, ImmunoWay, Newark, DE, USA); rabbit polyclonal anti-Akt1 
(1:1000, ImmunoWay, Newark, DE, USA); rabbit polyclonal anti-phospho-Akt (Ser473, 
1:1000, ImmunoWay, Newark, DE, USA); rabbit polyclonal anti-mTOR (1:5000, 
ImmunoWay, Newark, DE, USA); rabbit polyclonal phospho-mTOR (Ser2448, 1:5000, 
Immuno-Way, Newark, DE, USA); rabbit polyclonal anti-EAAT1 (1:500, ImmunoWay, 
Newark, DE, USA), and mouse monoclonal anti-EAAT2 (1:500, Abcam, HongKong, 
China). After extensive washing with TBST, the blots were probed with horseradish 
peroxidase-conjugated goat anti-mouse IgG (1:5000, ZSGB-BIO, Beijing, China) or anti-
rabbit IgG (1:10000, ZSGB-BIO, Beijing, China) diluted in blocking buffer for 1 h at room 
temperature. The immunoreactive bands were visualized using enhanced 
chemiluminescence (ECL, Millipore, Bedford, MA, USA) and (Kodak). Band density values 
of individual proteins were normalized by β-actin (1:5000, Santa Cruz Biotechnology, CA, 
USA) and measured using ImageJ software (NIH, Bethesda, MD, USA). Results were 
means of three replicates of experiments.
Immunofluorescence Staining
After treatment with Aβ, the slides were fixed with 4 % paraformaldehyde (Solarbio, China, 
Beijing) for 30 min. After three rinses with PBS, cells were incubated with 0.5 % Triton 
X-100 (DingGuo, Beijing, China) for 15 min and blocked with 10 % goat serum (ZSGB-
BIO, Beijing, China) for 30 min at 37 °C. Subsequently, the astrocytes were incubated with 
primary antibodies at 4 °C overnight (mouse monoclonal anti-GFAP, 1:100, Abcam, 
Cambridge, UK). After adequate washing, rhodamine (TRITC)-conjugated goat anti-mouse 
IgG (1:200, ZSGB-BIO, Beijing, China) was added to the samples and incubated at 37 °C 
for 1 h in the dark. Finally, the slides were washed extensively and stained with 4′,6′-
diamidino-2-phenylindole (DAPI, Boisynthesis Biotechnology, Beijing, China) for 2 min at 
room temperature. Images were obtained at ×200 magnification under a fluorescent 
microscope (DP72, Olympus, Tokyo, Japan). Densitometry quantification was performed 
using ImageJ (NIH, Bethesda, MD, USA) software after converting the image to gray scale. 
All experiments were performed in triplicates.
MTT Reduction Test
Cell viability was examined through conversion of methyl thiazolyl tetrazolium (MTT, 
Sigma, Saint Louis, MO, USA) to colored formazan crystals. Briefly, medium in each well 
was replaced with 180 μL FBS-free DMEM containing 20 μL of 5 mg/mL MTT, and the 
astrocytes were incubated for 4 h. At termination, MTT was removed by aspiration and the 
formazan crystals were solubilized by 200 μL DMSO, and then the cultures were incubated 
for an additional 20 min. The optical density was measured at a test wavelength of 570 nm 
and a reference wavelength of 630 nm using a spectrophotometer. Results are expressed as 
percent of control values.
Data Analysis
Results are expressed as mean ± SD. To determine the significance of difference among 
various groups, the statistical analysis was performed by one-way analysis of variance 
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(ANOVA) followed by Tukey’s test using SPSS 17.0. p < 0.05 was considered statistically 
significant in all tests.
Results
Identification of Aβ1–42 Oligomers
Transmission electron microscope analysis showed that the oligomers were regular and 
uniform spheres with a diameter of 12–25 nm, and no fibrillar aggregates were present in 
this preparation (Fig. S1). The magnification of the images is ×100,000 and the scale bar is 
250 nm. Our results suggested that the Aβ1–42 oligomers used in this experiment were 
acceptable for experiments.
Aβ1–42 Oligomers-Induced Reactive Astrogliosis
Glial fibrillary acidic protein (GFAP), widely used as an indicator of astrocyte activation, is 
progressively increased in AD. Furthermore, it is correlated with severity of AD pathologic 
changes (Wharton et al. 2009). Therefore, we treated the astrocytes with different 
concentrations of Aβ1–42 oligomers to simulate the different stages of AD, and then detected 
the changes of GFAP at the gene and protein levels. First, our real-time RT-PCR and 
Western blot results showed that expression of GFAP was increased by the Aβ1–42 oligomers 
in a dose-dependent manner (Fig. 1a–c, p < 0.05). Subsequently, we found that Aβ could 
cause morphological changes of the astrocytes, namely enlarged cell bodies and nuclei, 
hypertrophic processes, and increased GFAP expression. Furthermore, there was an absence 
of cell proliferation (Fig. 1d, e, p < 0.05).
Aβ1–42 Oligomers and Insulin Changed the Expression of Insulin Receptor in Astrocytes
Brain IRs that are densely localized on the hippocampus and entorhinal cortex contribute to 
learning and memory, and are activated by tyrosine autophosphorylation of β subunits when 
insulin binds to α subunits. This receptor and its tyrosine kinase activity are substantially 
lost in AD brain, which could be markedly prevented by insulin (Talbot et al. 2012). To 
explore the impact of Aβ1–42 oligomers and insulin on IRs in astrocytes, we employed real-
time RT-PCR analysis demonstrating that mRNA encoding IR was decreased by Aβ in a 
dose-dependent manner (Fig. 2a, p < 0.05). In addition, the protein levels of IR-α, IR-β, and 
p-IR at Tyr1361 were evaluated by Western blot analysis. We found that lower expressions 
of IR-α and IR-β, as well as a reduction in p-IR at Tyr1361, were potentiated with 
concentrations of the Aβ1–42 oligomers (Fig. 2b–e, p < 0.05). Although insulin treatment for 
30 min had no effects on IR mRNA (Fig. 2a, p > 0.05), we found a significant effect on IR-
α, IR-β and phosphoryla-tion of IR after exposure to insulin compared with their respective 
control groups (Fig. 2b–e, p < 0.05). In addition, the ratio of p-IR/IR-β was also raised by 
insulin (Fig. 2f, p < 0.05), meaning that the increment of p-IR was more than IR-β after 
insulin treatment.
Aβ1–42 Oligomers and Insulin Altered the Expression of Protein Kinase B in Astrocytes
Akt, a component of the insulin signal pathway, has been shown to have beneficial functions 
in the brain, such as improving cell survival and promoting protein synthesis. It is detectable 
in astrocytes and can respond to growth factors including insulin. Additionally, it has been 
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shown that the reduced phosphorylation of Akt is closely associated with increased 
intracellular Aβ levels (Lee et al. 2009), and insulin completely reverses this tendency (Yang 
et al. 2013). To determine whether Akt was affected by Aβ and insulin in astrocytes, we 
initially measured mRNA expression by real-time RT-PCR analysis and found that Akt 
mRNA was unchanged after incubation with Aβ1–42 oligomers or insulin (Fig. 3a, p >0.05). 
To determine the total protein and phosphorylation of Akt, we employed Western blot 
analysis and found that Akt total protein was unaltered (Fig. 3b, c, p >0.05), whereas Akt 
phosphorylation at Ser473 was significantly decreased by the soluble Aβ1–42 oligomers (Fig. 
3b, d, p <0.05). Moreover, we also observed that insulin enhanced the phosphorylation of 
Akt compared with the control groups (Fig. 3b, d, p <0.05) but had no influ-ence on total 
protein of Akt (Fig. 3b, c, p >0.05). Furthermore, the ratio of phospho-protein kinase B (p-
Akt)/Akt was also increased by insulin (Fig. 3e, p <0.05).
Aβ1–42 Oligomers and Insulin Changed the Expression of Mammalian Target of Rapamycin 
in Astrocytes
mTOR, a downstream target of Akt, is a key regulator of protein translation. It has been 
reported that its activity is directly linked to cell survival, axon guidance, protein synthesis, 
synaptic plasticity, and memory formation (Hulmi et al. 2012; Machado-Neto et al. 2011). 
To assess whether the mRNA of mTOR was modulated by Aβ and insulin, our real-time RT-
PCR analysis demonstrated no significant differences among each group (Fig. 4a, p >0.05). 
To evaluate whether the protein levels of mTOR were affected by Aβ and insulin, we 
conducted further Western blot analysis. In our experiments, total protein of mTOR 
remained constant among all groups (Fig. 4b, c, p >0.05). However, decreased levels of 
phospho-mammalian target of rapamycin (p-mTOR) at Ser2448 were observed in the 
astrocytes by treatment with Aβ1–42 oligomers in a dose-dependent manner, which were 
reversed by insulin treatment for 30 min (Fig. 4b, d, p < 0.05). The ratio of p-mTOR/mTOR 
was also reduced by Aβ and increased by insulin in group III, group IV, and group V (Fig. 
4e, p <0.05).
Aβ1–42 Oligomers and Insulin Changed the Expression of Excitatory Amino Acid 
Transporters in Astrocytes
EAAT1 and EAAT2 are expressed exclusively in astrocytes and are responsible for the bulk 
of glutamate uptake, which is a major mechanism that prevents excessive glutamate 
accumulation in the synaptic space and thus protects neurons from excitotoxicity. In the 
normal brain, both EAAT1 and EAAT2 are detectable in the hippocampus, a region of the 
brain that participates in learning and memory (Jacob et al. 2007). To determine whether the 
expressions of EAAT1 and EAAT2 were regulated by Aβ and insulin, we employed RT-PCR 
and found that the mRNA levels were not affected by these two drugs (Fig. 5a, b, p > 0.05). 
Subsequently, our Western blot results showed that the protein expressions of EAAT1 and 
EAAT2 were both lowered by the Aβ1–42 oligomers, whereas they were increased by insulin 
(Fig. 5c–e, p < 0.05).
Cell Viability of the Astrocytes was Affected by Aβ1–42 Oligomers and Insulin
To further evaluate whether alteration of the insulin/Akt/ EAAT signaling pathway was 
associated with changes in cell viability, we incubated the astrocytes with Aβ1–42 oligomers 
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and insulin and performed MTT analysis. Incubation with Aβ1–42 oligomers at 100 nM and 
1 μM for 24 h caused a significant decrease of MTT reduction (23 and 70 %, respectively), 
whereas insulin exposure for 30 min induced an approximate 10 % increase of MTT 
reduction in both group IV and group V compared with the control groups (Fig. 6, p <0.05), 
suggesting that Aβ1–42 oligomers at 100 nM and 1 μM were toxic to the astrocytes and 
insulin at 100 nM had protective functions to the cells in the presence of Aβ1–42 oligomers 
at 100 nM and 1 μM (p < 0.05).
Discussion
Aβ deposition in the brain is a crucial step in the onset and progress of AD through 
interference with a number of signaling cascades. However, the precise molecular pathway 
remains to be elucidated. It has been proposed as an initiating event in AD, and other 
neuropathologic features might be the consequence of aberrant accumulation of Aβ. 
Notably, it could disturb neuronal insulin signaling by desensitizing IRs, thus contributing to 
insulin resistance (de la Monte 2012). Therefore, we chose Aβ treatment of astrocytes as a 
cell culture AD model and adopted a modified method to prepare Aβ1–42 oligomers that 
could be kept in a stable state at −80 °C for an extended period of time so that it did not have 
to be used immediately after its preparation. Four weeks later, we detected Aβ1–42 oligomers 
with only traces of fibrillary aggregates (data not shown). This study aimed to investigate 
whether the disturbance in insulin/Akt/EAAT signaling was involved in AD pathogenesis 
and if insulin was a protective factor.
Astrocytes, which are basic components of the brain support system, play a critical role in 
controlling ion and transmitter concentration, regulating brain-blood barrier, resisting 
noxious substances, preserving connections in brain networks, maintaining synaptic birth 
and maturation, coordinating neuronal activity, and aiding in cognition (Giaume et al. 2007; 
Gibbs et al. 2008). Aβ appears to induce reactive astrogliosis, especially at higher 
concentrations (Fig. 1). When transforming into a reactive state, astrocytes lose their normal 
physiologic functions. Consequently, astrocyte malfunction might cause lesions to the CNS 
and play a central role in triggering a cascade, ultimately leading to neurodegenerative 
disease. It has been shown recently that astrocytes are actively involved in the inflammatory 
events associated with Alzheimer-type pathology (Avila-Munoz and Arias 2014) and 
astrocyte activation is discovered in the early stages of AD (Carter et al. 2012; Olabarria et 
al. 2010). Therefore, it is of great value to investigate changes in astrocytes in AD. Because 
there is much distinction between human astrocytes and rodent astrocytes in terms of 
morphology, physiology, and function (Sukhorukova et al. 2012), human cells are more 
suitable to study AD pathogenesis. However, primary cultured astrocytes from the human 
cerebral cortex are always difficult to obtain, thus we chose the cell line HA-1800 (Wang et 
al. 2013) for our research.
Brain insulin signaling is responsible for neuroendocrine function and cognition. An 
overview of this signal transduction pathway is shown in Fig. 7 (Franke 2008; Hers et al. 
2011; Laplante and Sabatini 2009; Wu et al. 2010). Briefly, insulin binding to IR-α induces 
dimerization and autophosphorylation of IR-β, which subsequently triggers Akt 
phosphorylation at Ser473; mTOR is a downstream target of Akt. Hence Akt activation can 
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result in increased phosphorylation of mTOR at Ser2448 and then induce EAAT protein 
synthesis. Moreover, all substrates have been detected in neurons and glial cells (On 2013a), 
and our previous study indicated that aberrant insulin signaling was present in AD (Han et 
al. 2012; Zhang et al. 2015). In this paper, we present evidence from cell cultures that 
alteration of the insulin/Akt/EAAT signaling cascade might be one of the potential 
pathogenesis of AD and insulin is capable to protect human astrocytes when oli-gomeric 
beta amyloid is added. First, we showed that Aβ1–42 oligomers decreased the levels of IR 
mRNA and IR protein and blocked IR activation in the astrocytes (Fig. 2). Persistent 
suppression of IR can cause brain insulin resistance. Moreover, the ratio of p-IR to IR was 
lessened by Aβ1–42 oligomers in a dose-dependent manner (Fig. 2f), meaning that the 
reduction of IR phosphorylation at Tyr1361 was more obvious than total IR expression when 
Aβ1–42 oligomers was added. Furthermore, it was revealed that the decrease in p-Akt 
occurred in brains from rats with type 2 diabetes; a disease that disrupts the common cellular 
and molecular pathways associated with AD (Correia et al. 2012; Yang et al. 2013). In 
addition, Aβ could cause reductions in mTOR phosphorylation at the Ser2448 site (Lafay-
Chebassier et al. 2005, 2006). The findings are consistent with our observations that the 
astrocytes exhibited a striking loss of p-Akt at Ser473 and p-mTOR at Ser2448 (Figs. 3b, d, 
4b, d). mRNA and total protein levels of both these kinases were similar to that of the 
control groups (Figs. 3a–c, 4a–c). We speculate that there might be three explanations for 
this phenomenon. First, Aβ can remove IR via Aβ-triggered endocytosis or by disturbing 
gene transcription and protein translation or by destroying the IR mRNA and protein 
directly. Second, Aβ may interfere with the modifications of Akt and mTOR proteins, rather 
than affect the gene transcription and protein translation directly. Third, the impairment of 
IR or p-IR might interfere with the phosphorylation of Akt and mTOR through the insulin 
signaling pathway. However, the specific mechanism is still unknown and further research 
will be needed. On the contrary, increased phospho-Ser473 Akt was reported in AD patients 
(Griffin et al. 2005).This divergence may be due to the different degrees of the disease and 
the diverse regions of the pathological changes. In addition, several studies showed neuronal 
PI3 K/Akt/ mTOR signaling was activated aberrantly and sustainedly in AD brain (On 
2013b; Gupta and Dey 2012), this is mechanistically linked to progressive desensitization of 
insulin responses. More detailed studies will be necessary to clarify this point.
Glutamate is the main excitatory neurotransmitter in the brain. Excessive glutamate 
accumulation in the extracellular spaces triggers excitotoxic neuronal damage, which has 
been implicated in many neurodegenerative disorders including AD. There are no enzymes 
for metabolizing this neurotransmitter in the synaptic space and the main pathway to 
maintain glutamate homeostasis is its reuptake via EAAT1 and EAAT2 (Danbolt 2001). It 
was reported that the loss of EAAT can impair glucose utilization and promote CNS 
dysfunction over time (Cassano et al. 2012). In our experiment, although the mRNA levels 
of EAAT1 and EAAT2 were unchanged, the protein expressions were reduced by the Aβ1–42 
oligomers (Fig. 5). We concluded that the capacity of glutamate clearance was attenuated by 
Aβ. There are conflicting results demonstrating that Aβ could upregulate glutamate 
transporters in primary cultured cortical astrocytes or in mice brains (Peters et al. 2009). It 
may be a compensatory reaction a low dose of Aβ can increase the expressions of EAAT1 
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and EAAT2 at the early stage of AD, whereas a high burden of Aβ may cause injury to these 
transporters, which results in the disturbance of glutamate recycling.
Insulin contributes to cognition, cerebral glucose metabolism, potentiation of synaptic 
responses, and regulation of neuronal survival through the insulin signaling pathway. In 
addition, insulin can attenuate pathogenic binding of Aβ and synaptic deficits (Chen et al. 
2014). Although insulin mRNA and insulin protein synthesis is not measurable in astrocytes, 
these glial cells could be influenced by insulin (Henneberger et al. 2010). It has been 
reported that IR and p-IR expressions are markedly raised by insulin in neurons (Jolivalt et 
al. 2008). In our experiment, insulin induced a significant increase in IR protein and its 
phosphorylation at Tyr1361 without altering IR mRNA in astrocytes (Fig. 2). Furthermore, 
we found that insulin enhanced the levels of p-Akt at Ser473 and p-mTOR at Ser2448 (Figs. 
3b, d, 4b, d), and we also showed that protein expressions of EAAT1 and EAAT2 were both 
improved by insulin compared with the control groups (Fig. 5). As a consequence, we 
deduce that insulin can compete with Aβ and reduce the affinity of Aβ binding to the 
remaining IRs, thereby triggering the activation of insulin signaling. Moreover, we 
uncovered an adverse effect of Aβ1–42 oligomers on astrocyte survival and a considerably 
beneficial role of insulin in improving cell viability (Fig. 6). Randomized and double-blind 
trials have proved that intranasal insulin therapy improves cognitive function in patients with 
mild cognitive impairment or with AD (Craft et al. 2012). However, others have shown that 
chronically high insulin levels might be deleterious to the brain (Cole and Frautschy 2007). 
One possible explanation for this inconsistency might be the different drug doses or diverse 
administration routes of insulin. Together, large-scale investigations are essential to explore 
the status and efficacy of insulin therapy.
In conclusion, the present study demonstrated that soluble Aβ oligomers could disrupt the 
glutamate metabolic system in astrocytes by perturbing insulin signaling and impairing 
EAATs. Subsequently, astrocytes lose their neuroprotective ability and induce neuronal 
injury. In addition, our data also indicate that insulin activated protective functions for the 
astrocytes, even though chronically high levels in the brain might be deleterious.
The limitations of this study are that experiments in vivo were not done, and the precise 
interaction mechanism among these signaling proteins has not been elucidated. However, 
this study does suggest that strategies aimed at restoring astrocytic function might be a 
potential treatment for AD, and insulin or drugs designed to specifically enhance CNS 
insulin signaling may provide therapeutic benefits for the treatment of AD.
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Reactive astrogliosis was induced by the Aβ1–42 oligomers: a mRNA levels of GFAP (F = 
67.304, *p < 0.05); b representative western blot bands of GFAP; c densitometric 
measurements of GFAP normalized by β-actin (F = 9.443, *p < 0.05); d representative 
figures of GFAP immunofluorescence stain; DAPI, nuclei; TRITC, GFAP; e densitometry 
quantification of GFAP immunofluorescence stain (F = 67.399, *p <0.05)
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Changes of IR mRNA and protein expression induced by Aβ1–42 oligomers and insulin: a 
mRNA levels of IR (F = 24.952, *p < 0.05); b representative western blot bands of IR-α, IR-
β and p-IR at Tyr1361; c densitometric measurements of IR-α normalized by β-actin (F = 
242.107, *p < 0.05); d densitometric measurements of IR-β normalized by β-actin (F = 
70.964, *p < 0.05); e densitometric measurements of p-IR normalized by β-actin (F = 
176.129, *p < 0.05); f the ratio of p-IR/IR-β (F = 27.365, *p < 0.05)
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Changes in Akt mRNA and protein expression induced by Aβ1–42 oligomers and insulin: a 
mRNA levels of Akt (F = 0.193, p > 0.05); b representative Western blot bands of Akt; c 
densitometric measurements of Akt normalized by β-actin (F = 1.415, p > 0.05); d 
densitometric measurements of p-Akt normalized by β-actin (F = 172.558, *p < 0.05); e The 
ratio of p-Akt/Akt (F = 102.084, *p < 0.05)
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Changes in mTOR mRNA and protein expression induced by Aβ1–42 oligomers and insulin: 
a mRNA levels of mTOR (F = 0.149, p > 0.05); b representative Western blot bands of 
mTOR; c densitometric measurements of mTOR normalized by β-actin (F = 0.470, p > 
0.05); d densitometric measurements of p-mTOR normalized by β-actin (F = 124.794, *p < 
0.05); e The ratio of p-mTOR/mTOR (F = 64.520, *p <0.05)
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Changes in EAAT1 and EAAT2 induced by Aβ1–42 oligomers and insulin: a mRNA levels 
of EAAT1 (F = 0.362, p > 0.05); b mRNA levels of EAAT2 (F = 0.092, p > 0.05); c 
representative western blot bands of EAAT1 and EAAT2; d densitometric measurements of 
EAAT1 normalized by β-actin (F = 312.936, *p < 0.05); e densitometric measurements of 
EAAT2 normalized by β-actin (F = 95.475, *p < 0.05)
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Cell viability was measured by MTT reduction: Aβ1–42 oligomers at 100 nM and 1 μM 
induced a significant decrease in MTT reduction compared with the control group and 
insulin exposure increased the MTT reduction in the presence of Aβ1–42 oligomers at 100 
nM and 1 μM in both group IV and group V (F = 185.142, *p < 0.05)
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Schematic representation of insulin/Akt/EAAT signaling pathway. a Insulin binding to IR-α 
induces dimerization and autophosphorylation of IR-β, which subsequently triggers Akt 
phosphorylation. mTOR is an important downstream target of Akt, and Akt activation can 
result in increased phosphorylation of mTOR, which then induces EAAT protein synthesis. 
b Aβ oligomers can destroy the IRs, disrupting expression of the downstream substrates and 
disturbing glutamate metabolism
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